Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia

MLA

Megan E. Zavorka Thomas, et al. “Gilteritinib-Induced Upregulation of S100A9 Is Mediated through BCL6 in Acute Myeloid Leukemia.” Blood Advances, vol. 5, Dec. 2021, pp. 5041–46. EBSCOhost, https://doi.org/10.1182/bloodadvances.2021005614.

APA

Megan E. Zavorka Thomas, Navjot Pabla, Daelynn R. Buelow, Sharyn D. Baker, Alex Sparreboom, Jae Yoon Jeon, Josie A. Silvaroli, Moray J. Campbell, & Zahra Talebi. (2021). Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia. Blood Advances, 5, 5041–5046. https://doi.org/10.1182/bloodadvances.2021005614

Chicago

Megan E. Zavorka Thomas, Navjot Pabla, Daelynn R. Buelow, Sharyn D. Baker, Alex Sparreboom, Jae Yoon Jeon, Josie A. Silvaroli, Moray J. Campbell, and Zahra Talebi. 2021. “Gilteritinib-Induced Upregulation of S100A9 Is Mediated through BCL6 in Acute Myeloid Leukemia.” Blood Advances 5 (December): 5041–46. doi:10.1182/bloodadvances.2021005614.